UPDATE: Stifel Starts Verve Therapeutics (VERV) at Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Verve Therapeutics (VERV) Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease
September 23, 2021 6:31 AM EDTVerve Therapeutics, (Nasdaq: VERV) a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported data from a new preclinical study in 36 non-human primates (NHPs) with its lead clinical candidate, VERVE-101, a potential single-course gene editing treatment for atherosclerotic cardiovascular disease (ASCVD). Findings from that study as well as additional studies in rodents demonstrated potent and durable lowering of... More
